Sep 23, 2021 / 04:00PM GMT
Sara Parigian - LifeSci Advisors, LLC - VP of KOL Strategy & Management
Good afternoon, and welcome to the Y-mAbs Therapeutics KOL Webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma. At this time, all attendees are in a listen-only mode. A live verbal question-and-answer session will follow today's formal presentation. This webinar is not being recorded, and there will be no replay made available following the conclusion of today's event.
I would now like to turn the call over to your host, Thomas Gad, Chairman, Founder and President of Y-mAbs Therapeutics. Please go ahead, Thomas.
Thomas Gad - Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy
Thank you, Sara. Before we begin, let me just remind everyone that today contains -- today's discussion contains forward-looking statements as defined by the Reform Act of 1995, the disclaimers here. With that said, we are very pleased today to have Dr. Jaume Mora from Hospital Sant Joan de Deu in Barcelona, probably one of the biggest
Y-mAbs Therapeutics Inc to Host Key Opinion Leader Webinar on DANYELZA® - Conference Call Transcript
Sep 23, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers